U.S. Food and Drug Administration
Topic Paragraphs
Featured Topics
FDA.gov Website Refresh
FDA is pleased to announce the launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience.
Fostering Drug Competition
Increasing the availability of generic drugs helps to create competition in the marketplace, helping make treatment more affordable and increasing access to healthcare for more patients.
Combating the Opioid Crisis
FDA takes actions to combat prescription opioid abuse.
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
May 17
U.S Trading Recalls RATTAN SHOOTS in BRINE Due to Undeclared Sulfites
Food & Beverages
May 17
Coolhaus Issues Voluntary Recall on Dairy Free Horchata Frozen Dessert Sandwich
Food & Beverages
May 15
Brodt Zenatti Holding LLC Recalls Karawan Brand Tahini Because Of Possible Health Risk
Food & Beverages
FDA Voices: Perspectives from FDA Experts
FDA’s Global Inspection Program Helps Ensure Generic Drug Safety
FDA stands behind the rigorous standards and regulatory inspections that go into ensuring the safety and quality of all generic drugs.
FDA's Generic Drug Priorities: Safety, Efficacy, and Expanded Access
The agency continues to work to ensure a supply of safe, effective, and cost-saving generic drugs, each manufactured under our rigorous quality standards.
FDA's Nutrition Innovation Strategy Makes Great Progress in First Year
The agency is committed to empowering consumers with nutritional information, and is encouraging industry to make healthier options available in the marketplace.
Recently Published Guidances
May 17
Draft Guidance for Industry: The Use of an Alternate Name for Potassium Chloride in Food Labeling
Food & Beverages
May 09
Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry
Drugs
May 09
Determining Whether to Submit an ANDA or a 505(b)(2) Application
Drugs